期刊文献+

老年慢性心力衰竭患者血浆NT-proBNP、U-Ⅱ和尿AQP-2变化的研究 被引量:4

Levels of plasma NT-proBNP,Urotensin Ⅱ and Urine aquaporin 2 in elderly patients with chronic heart failure
原文传递
导出
摘要 目的探讨老年慢性充血性心力衰竭(CHF)患者治疗前后血浆氮末端脑钠肽前体(NT-Pro BNP)、尾加压素Ⅱ(U-Ⅱ)和尿水通道蛋白2(AQP-2)的变化及临床意义。方法将2012年1月至2014年1月在我院住院的老年CHF患者230例做为观察组,其中纽约心脏病协会(NYHA)心功能分级Ⅱ级62例、Ⅲ级76例、Ⅳ级92例,另设同期健康体检者100例作为对照组,检测治疗前后血浆NT-Pro BNP、U-Ⅱ和尿AQP-2的含量,比较治疗前后及2组间水平变化及其相互关系。结果老年CHF患者治疗前血浆NT-Pro BNP水平显著高于对照组,不同心功能等级患者NT-Pro BNP均较对照组增高,与CHF心功能等级呈正相关(P<0.01);治疗后血浆NT-Pro BNP水平较治疗前明显降低,差异有统计学意义(P<0.01)。老年CHF患者治疗前血浆U-Ⅱ水平明显低于对照组,不同心功能等级U-Ⅱ值均低于对照组,与CHF心功能等级呈负相关(P<0.01);治疗后与治疗前相比血浆U-Ⅱ水平明显升高(P<0.01)。老年CHF患者治疗前后尿AQP-2水平及变化趋势与血浆NT-Pro BNP变化趋势一致(P<0.01)。血浆NT-Pro BNP水平与血浆U-Ⅱ水平呈负相关,与尿AQP-2呈正相关(P<0.01)。结论血浆NTPro BNP、U-Ⅱ和尿AQP-2与心功能等级相关,在CHF的发生发展中发挥着重要作用。 Objective To investigate the levels of plasma N-terminal pro-brain natriuretic peptide( NT-pro BNP),urotensin Ⅱ( U-Ⅱ) and urine aquaporin 2( AQP-2) of elderly patients with chronic heart failure( CHF) before and after treatment. Methods 230 hospitalized CHF patients from January 2012 to January 2014 in Nanjing General Hospital of Nanjing Military Region were analyzed. According to classification of function capacity of the NYHA,the cardiac functional grading of the patients were grade Ⅱ( 62 cases),gradeⅢ( 76 cases) and grade Ⅳ( 92 cases). Meanwhile,100 healthy controls were enrolled. The levels of plasma NT-pro BNP,U-Ⅱ and urine AQP-2 were tested and compared. Results Before treatment,compared with the healthy control,plasma NT-Pro BNP in CHF patients was significantly higher( P〈0. 01). NT-Pro BNP significantly increased in different CHF grades,and were positively correlated with heart function classification( P〈0. 01). After treatment,plasma NT-Pro BNP level was significantly decreased( P〈0. 01). Plasma U-Ⅱ in CHF patients was significantly lower than that in healthy controls and was negatively correlated with heart function classification( P〈0. 01). After treatment,the plasma U-Ⅱ of the CHF patients was significantly increased( P〈0. 01). Urine AQP-2 showed the same trend with plasma NT-Pro BNP in the patients. Plasma NT-Pro BNP was negatively correlated with U-Ⅱ and positively correlated with urine AQP-2( P〈0. 01). Conclusions Plasma NT-pro BNP,U-Ⅱ and urine AQP-2 are corresponding with heart function classification,which may play an important role in the development of CHF.
出处 《实用老年医学》 CAS 2015年第4期303-306,共4页 Practical Geriatrics
关键词 充血性心力衰竭 氮末端脑钠肽前体 尾加压素Ⅱ 水通道蛋白2 chronic heart failure N-terminal pro-brain natriuretic peptide urotensin Ⅱ aquaporin 2
  • 相关文献

参考文献8

二级参考文献81

  • 1富路,戴颖楠,朱立群,万晓京,曹君娴,韩颖,谢荣盛.慢性心功能衰竭患者血浆尾加压素Ⅱ、内皮素和肾上腺髓质素的变化[J].中国动脉硬化杂志,2007,15(3):201-204. 被引量:9
  • 2方放,黄方,张瑗,钱晓明.老年充血性心力衰竭患者稀释性低钠血症与心功能等级的关系分析[J].实用老年医学,2013,27(6):474-476. 被引量:2
  • 3是若春,方雷,刘龙.APACHEⅡ危重病评分系统在ICU的应用[J].中华急诊医学杂志,2005,14(9):783-784. 被引量:42
  • 4王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 52009 focus update:ACCF/AHA guideline for the diagnosis and management of heart failure in adults [ J ]. Circulation, 2009, 119 : e391.
  • 6Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guideline for the diagnosis and treatment of acute and chronic heart failure 2008 : The Task Force for the Diagnosis and Treardiology. Developed in collaboration with HFAand endorsed by(ESIM) [J]. Eur Heart J, 2008, 29(19) : 2388.
  • 7Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronm7 arterv disease and left-ventricular systolic dysfunction ( BEAUTIFUL) : a suhglmalysis of a randomised controlled trial[ J]. Lancet, 2008, 372(9641) : 817-821.
  • 8Swedberg K, K,,majda M, Bahm M, et al. Ivabradine and outcomes in chronic heart failure ( SHIFT ) : a randomised placebo-controlled study [ J ]. Lancet, 2010, 376(9744) : 875-885.
  • 9McMurray JJ, Swedberg K. HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure-lessons learnt from a decade of trials[ J]. Eur J Heart Fail, 2010, 12(2) : 99-103.
  • 10Danbert C, Gold MR, Abraham WT, et ah Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction : insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial[J]. J Am Coil Cardiol, 2009, 54(20) : 1837-1846.

共引文献3858

同被引文献39

引证文献4

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部